Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
9.15
-0.13 (-1.40%)
At close: Jun 27, 2025, 4:00 PM
9.12
-0.03 (-0.33%)
After-hours: Jun 27, 2025, 7:56 PM EDT
Sage Therapeutics Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for Sage Therapeutics stock ranges from a low of $4.00 to a high of $26. The average analyst price target of $10.06 forecasts a 9.95% increase in the stock price over the next year.
Price Target: $10.06 (+9.95%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sage Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 15 | 15 | 15 | 14 | 14 | 15 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 20 | 20 | 20 | 19 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Hold Maintains $7 → $9 | Hold | Maintains | $7 → $9 | -1.64% | Jun 20, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $9 → $8.5 | Buy → Hold | Downgrades | $9 → $8.5 | -7.10% | Jun 17, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | -1.64% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +31.15% | Jun 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $8 → $8.5 | Hold | Maintains | $8 → $8.5 | -7.10% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
83.40M
from 41.24M
Increased by 102.21%
Revenue Next Year
119.27M
from 83.40M
Increased by 43.01%
EPS This Year
-3.67
from -6.59
EPS Next Year
-2.94
from -3.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.4M | 198.7M | 229.8M | ||
| Avg | 83.4M | 119.3M | 156.5M | ||
| Low | 61.7M | 78.4M | 110.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 230.7% | 138.2% | 92.7% | ||
| Avg | 102.2% | 43.0% | 31.2% | ||
| Low | 49.6% | -6.0% | -7.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.08 | -1.76 | -0.74 | ||
| Avg | -3.67 | -2.94 | -1.99 | ||
| Low | -3.90 | -3.85 | -3.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.